Eli Lilly and Company (NYSE: LLY) announced on April 27, 2026 a definitive agreement to acquire Ajax Therapeutics, Inc., a Cambridge and New York-based biopharmaceutical company developing next-generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs). The deal includes an upfront payment and subsequent payouts based on the achievement of certain clinical and regulatory milestones, with Ajax shareholders eligible to receive up to $2.3 billion in cash in total.
The acquisition marks Lilly’s third oncology-focused M&A deal of 2026 and underscores the company’s accelerating push to reshape its cancer portfolio around differentiated, mechanism-driven therapies.
A First-in-Class Mechanism Targeting an Unmet Need
At the heart of the deal is AJ1-11095, a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026.
The distinction between Type I and Type II JAK2 inhibition is scientifically significant. All approved JAK2 inhibitors for patients with MPNs, including myelofibrosis and polycythemia vera, bind the Type I confirmation of JAK2. While these JAK2 inhibitors provide clinical and symptomatic relief, many patients often discontinue Type I JAK2 treatment due to a lack of durable benefit or loss of response.
AJ1-11095 was engineered to overcome precisely this limitation. Based on its unique mode of binding JAK2, AJ1-11095 has the potential to deliver deeper and more durable disease control than approved therapies for myelofibrosis and polycythemia vera. The drug is also being developed for polycythemia vera, a related disorder in which the body overproduces red blood cells.
The therapy is currently being evaluated in a Phase I clinical trial (NCT06343805) in patients with myelofibrosis who have previously been treated with a Type I JAK2 inhibitor. Dose selection for future clinical development is expected in 2026.
Lilly’s Strategic Rationale: A Long-Term Bet
Lilly’s acquisition of Ajax was not an arms-length transaction, it was the logical culmination of a deepening strategic relationship. In 2024, the big pharma company participated in Ajax’s $95 million Series C financing round, making the company a founding strategic investor well before Monday’s announcement.
Jacob Van Naarden, Executive Vice President and President of Lilly Oncology and Head of Corporate Business Development, emphasized the scientific conviction behind the move:
As a founding strategic investor in Ajax, Lilly has long believed in the approach and is excited about the potential for AJ1-11095 to deliver deeper and more durable efficacy than available treatments with a tolerability profile that would allow for patients to remain on therapy longer and be used across both the first- and second-line settings.
Jacob Van Naarden/LinkedIn
Ajax CEO Martin Vogelbaum offered perspective on the company’s founding mission:
We started Ajax to build on the work of its five scientific founders, including Ross Levine, MD, chief scientific officer at Memorial Sloan Kettering Cancer Center and chair of Ajax’s scientific advisory board, who sought to develop a novel class of selective and more potent JAK2 inhibitors to address the significant unmet need of patients with MPNs.
Martin Vogelbaum/LinkedIn
Oncology M&A Momentum at Lilly
The Ajax deal does not stand in isolation. The purchases are part of Lilly’s effort to revamp its oncology pipeline under business unit head Jake Van Naarden, who joined the company in 2019 when it acquired his firm, Loxo Oncology. At the time, Chief Executive Officer Dave Ricks tasked Van Naarden with overhauling Lilly’s cancer business, which started with him killing the majority of the drugs that were in development.
Lilly has been using the windfall from its blockbuster diabetes and obesity drugs to invest in other areas, including cancer and gene therapy. It already sells Verzenio and Inluriyo for breast cancer, and recent deals have helped it expand into treatments for other tumor types.
Lilly’s Ajax buyout comes as the company continues its acquisition spree, with the pharma company having inked six M&A deals so far in 2026. Of these acquisitions, half have been oncology-focused. Agreements to acquire in vivo CAR-T developers Orna Therapeutics and Kelonia came in February and April respectively.
Read more insights on Lilly’s previous acquisitions covered by OncoDaily Biotech below:
Competitive Landscape: The MPN Space Heats Up
The myeloproliferative neoplasm space is attracting significant attention across the industry. Despite its domineering M&A activity, Lilly is not the only company taking an acquisition-heavy strategy, as GSK and Gilead Sciences have also inked two and three multi-billion-dollar M&A deals, respectively, in 2026. This uptick in activity can be, in part, linked to the upcoming patent cliff faced by the pharma industry, which companies are looking to offset by pipeline restocks.
In the MPN space specifically, Sanofi recently took a bet on Sino Biopharma’s myelofibrosis drug, rovadicitinib, in a licensing deal worth up to $1.53 billion, which will see the French pharma company develop the therapy for chronic graft versus host disease (cGVHD) in post-transplant patients.
Lilly’s Type II JAK2 approach, if validated by the upcoming proof-of-concept data, would represent a genuinely differentiated mechanism in a competitive space where resistance to existing therapies remains a persistent clinical challenge.
Looking Ahead
The deal is subject to customary closing conditions, including Hart-Scott-Rodino antitrust clearance. Lilly plans rapid advancement toward registrational trials and will reflect the transaction in its GAAP financials after close.
With proof-of-concept data from the Phase 1 AJX-101 trial expected before year-end 2026 and dose selection underway, the timeline to registrational development could compress quickly, provided the clinical data delivers on the mechanistic promise. For Lilly, the Ajax acquisition is not simply a pipeline addition; it is a statement of intent about where next-generation blood cancer treatment is headed.
Read more biotech insights on OncoDaily Biotech.
Written by: Semiramida Nina Markosyan, Editor, OncoDaily Canada